| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Advancing patient-centricity in Medical Affairs: A survey of patients and patient organizations
|
Amin, Dahlia
|
|
|
28 |
7 |
p.
|
article
|
| 2 |
A new era for schizophrenia drug development – Lessons for the future
|
Granger, Kiri T.
|
|
|
28 |
7 |
p.
|
article
|
| 3 |
A personalized pharmaco-epistatic network model of precision medicine
|
Feng, Li
|
|
|
28 |
7 |
p.
|
article
|
| 4 |
Contents page
|
|
|
|
28 |
7 |
p.
|
article
|
| 5 |
Cubosome-based cosmeceuticals: A breakthrough in skincare
|
Shetty, Srishti
|
|
|
28 |
7 |
p.
|
article
|
| 6 |
Diary – July 2023
|
|
|
|
28 |
7 |
p.
|
article
|
| 7 |
Drug repurposing: Known knowns to unknown unknowns – Network analysis of the repurposome
|
Cavalla, David
|
|
|
28 |
7 |
p.
|
article
|
| 8 |
Dual-target inhibitors of PARP1 in cancer therapy: A drug discovery perspective
|
Zhang, Jiahui
|
|
|
28 |
7 |
p.
|
article
|
| 9 |
Fungal quorum-sensing molecules and antiseptics: A promising strategy for biofilm modulation?
|
Karine Marcomini, Emilli
|
|
|
28 |
7 |
p.
|
article
|
| 10 |
Keeping apace on the pharmaceutical treadmill
|
Kinch, Michael S
|
|
|
28 |
7 |
p.
|
article
|
| 11 |
Mechanistic insights into the beneficial effects of curcumin on insulin resistance: Opportunities and challenges
|
Balakumar, Pitchai
|
|
|
28 |
7 |
p.
|
article
|
| 12 |
Microbiota-sensitive drug delivery systems based on natural polysaccharides for colon targeting
|
Azehaf, Hajar
|
|
|
28 |
7 |
p.
|
article
|
| 13 |
Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases
|
Felten, Renaud
|
|
|
28 |
7 |
p.
|
article
|
| 14 |
Platelets and their derived extracellular vesicles: The new generation of markers in non-small cell lung cancer management
|
Tasso, Roberta
|
|
|
28 |
7 |
p.
|
article
|
| 15 |
Preclinical evaluation of chemically reactive metabolites and mitigation of bioactivation in drug discovery
|
He, Chunyong
|
|
|
28 |
7 |
p.
|
article
|
| 16 |
Reducing biopharmaceutical manufacturing costs through continuous processing in a flexible J.POD® facility
|
Garcia, Fernando A.
|
|
|
28 |
7 |
p.
|
article
|
| 17 |
Rodent models for anticancer toxicity studies: Contributions to drug development and future perspectives
|
Valerio de Mello Braga, Lara Luisa
|
|
|
28 |
7 |
p.
|
article
|
| 18 |
Scope of Wnt signaling in the precise diagnosis and treatment of breast cancer
|
Patel, Dilip K.
|
|
|
28 |
7 |
p.
|
article
|
| 19 |
SNAP@CQD as a promising therapeutic vehicle against HCoVs: An overview
|
Chatterjee, Satyaki
|
|
|
28 |
7 |
p.
|
article
|
| 20 |
Strategic trends of pharmaceutical companies: A growth model through regional focus and inter-regional alliances
|
Nakashima, Akinori
|
|
|
28 |
7 |
p.
|
article
|
| 21 |
Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates
|
Jin, Yu
|
|
|
28 |
7 |
p.
|
article
|
| 22 |
Targeting Rho kinase to restore endothelial barrier function following vascular scaffold implantation
|
Tesfamariam, Belay
|
|
|
28 |
7 |
p.
|
article
|
| 23 |
Targeting the endocannabinoid system: Structural determinants and molecular mechanism of allosteric modulation
|
Yuan, Jiayi
|
|
|
28 |
7 |
p.
|
article
|
| 24 |
The emerging role of fatty acid binding protein 5 (FABP5) in cancers
|
George Warren, William
|
|
|
28 |
7 |
p.
|
article
|
| 25 |
The recent progress of deep-learning-based in silico prediction of drug combination
|
Liu, Haoyang
|
|
|
28 |
7 |
p.
|
article
|
| 26 |
Treatment to cure: Advancing AAV gene therapy manufacture
|
Young, Paul
|
|
|
28 |
7 |
p.
|
article
|
| 27 |
US FDA 505(b)(2) NDA clinical, CMC and regulatory strategy concepts to expedite drug development
|
Salminen, William F.
|
|
|
28 |
7 |
p.
|
article
|
| 28 |
Virtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trials
|
Moingeon, Philippe
|
|
|
28 |
7 |
p.
|
article
|
Journal description